.Pharmacolibrary.Drugs.ATC.D.D05BB02

Information

Acitretin is an oral retinoid primarily used for the treatment of severe psoriasis and other disorders of keratinization. It is a second-generation, synthetic analog of vitamin A. Acitretin has been approved for clinical use in several countries, but is contraindicated in women of childbearing age due to its high teratogenic potential.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration of acitretin 50 mg.

References

1. Balato, N, et al., & Scarpa, R (2014). Managing moderate-to-severe psoriasis in the elderly. Drugs & aging 31(4) 233–238. DOI:10.1007/s40266-014-0156-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24554398

2. Geiger, JM, et al., & Saurat, JH (1994). Teratogenic risk with etretinate and acitretin treatment. Dermatology (Basel, Switzerland) 189(2) 109–116. DOI:10.1159/000246811 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8075435

3. Park, HD, et al., & Lee, SY (2009). A fully validated HPLC method for the simultaneous determination of acitretin and etretinate in plasma and its application to a pharmacokinetic study in healthy Korean subjects. International journal of clinical pharmacology and therapeutics 47(7) 476–482. DOI:10.5414/cpp47476 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19640355

Revisions

• 06/2025 initial generated model